In clinical practice, the high incidence of metabolic abnormalities, such as diabetes and hyperlipidemia, seen in schizophrenic patients are the result of a complex interaction of a number of factors, including lifestyle, overactivity of the hypothalamic-pituitary-adrenal axis, and antipsychotic medication. Antipsychotic-induced metabolic abnormalities have been thought to be due to insulin resistance caused by obesity, which is a major side-effect of antipsychotics. However, there is increasing evidence that second-generation antipsychotics can also have direct metabolic effects.

We investigated two similar groups of 9 non-obese, non-diabetic Japanese schizophrenic patients taking either risperidone or olanzapine as monotherapy for 3--66 weeks with no changes in their treatment for at least 3 weeks. The published Japanese definitions for obesity (BMI \>25, waist measurement at umbilicus level \>85 cm for males, \>90 cm for females) and diabetes (fasting glucose \> 110 mg/dL) were used ([@b5-ndt-3-177]).

Metabolic markers (glucose, insulin, triglycerides, total cholesterol, and high-density lipoprotein cholesterol) were measured in blood samples taken after 12 h fasting. Subjects then ingested a 110 g glucose tolerance test cookie ([@b2-ndt-3-177]) and blood was taken 2 h later for measurement of glucose, insulin, triglycerides, and remnant-like lipoprotein particles (RLP) cholesterol levels. Insulin resistance was assessed by the homeostasis model assessment of insulin resistance (HOMA-IR) ([@b1-ndt-3-177]). RLP were measured as the unbound serum fraction in an immuno-affinity mixed gel using monoclonal antibodies to apoA-I and apoB100 ([@b9-ndt-3-177]). RLP-cholesterol levels were determined as the cholesterol fraction.

Fasting values and those obtained 2 h after the glucose tolerance test are shown in [Table 1](#t1-ndt-3-177){ref-type="table"}. Plasma glucose levels remained within normal limits for both groups although those in the olanzapine group were significantly increased after the test compared with fasting levels. Insulin levels were significantly increased to a similar extent in both groups after the glucose tolerance test. No insulin resistance was seen in any patient.

The triglyceride levels were significantly increased compared to fasting levels in the olanzapine group but not in the risperidone group. The value over the normal limit (\>150 mg/dL) indicates that lipid metabolic abnormalities may occur in the olanzapine group. In addition, the level of RLP-cholesterol in the olanzapine group was also significantly increased compared to the risperidone group.

Higher fasting serum insulin levels have been found in schizophrenic patients treated with clozapine compared with those treated with conventional antipsychotics, suggesting possible insulin resistance ([@b6-ndt-3-177]). Similarly treatment with olanzapine resulted in elevated serum insulin levels compared to baseline values in a 5-month study ([@b7-ndt-3-177]).

These studies suggest that certain antipsychotics can induce insulin resistance. It is not clear, however, from these studies whether the effect results from metabolic syndromes, such as weight gain and obesity, or a direct effect.

Evidence for a direct effect is accumulating. A recent study of non-obese, non-diabetic schizophrenics showed elevated fasting insulin levels with clozapine and olanzapine ([@b3-ndt-3-177]). In this study, insulin resistance was significantly reduced in patients on clozapine or olanzapine compared with those on risperidone. In addition, in vitro studies have shown a direct effect of clozapine and olanzapine but not conventional antipsychotics on the stimulation of insulin secretion from pancreatic β-cells ([@b8-ndt-3-177]).

In the present study, non-obese and non-diabetic patients were selected, so that any lipid metabolic abnormalities that were seen were not due to any metabolic syndrome. Although no insulin resistance was found in the olanzapine treatment group, high levels of triglyceride and RLP-cholesterol were induced by the glucose tolerance cookie test. This suggests that olanzapine has a direct action on lipid metabolism even after relatively short treatment duration (3--24 weeks).

In contrast to the study by [@b3-ndt-3-177], the present study in non-obese, non-diabetic subjects found no difference between patients treated with olanazpine and risperidone in fasting insulin levels which were all within the normal range. A possible reason for this difference between the studies may be the duration of drug treatment. In the Henderson study, the mean duration of treatment with olanzapine was 29.5 months, whereas it was only 12.3 weeks in the present study. Another possibility is the influence of racial differences. Asian people have reduced insulin secretion compared with Caucasians ([@b10-ndt-3-177]), making it theoretically more difficult to detect metabolic abnormalities from fasting blood samples. This could explain why insulin resistance was not detected in our group of Japanese patients. The glucose tolerance test is clearly useful for earlier detection of lipid metabolic abnormalities. This is especially true for Japanese patients who have reduced insulin secretion compared with Caucasians and their metabolic abnormalities are not easily detected by conventional markers.

Higher levels of RLP-cholesterol have recently been suggested to be a risk factor for arteriosclerosis ([@b11-ndt-3-177]). In a 3-year follow-up study of patients with coronary artery disease, patients with higher RLP-cholesterol (\>5.1 mg/dL) had a significantly greater risk of developing coronary events than lower RLP-cholesterol patients (\<3.3 mg/dL) ([@b4-ndt-3-177]). The present study suggests that patients treated with olanzapine should be routinely tested using the glucose tolerance cookie test to determine RLP-cholesterol level as a risk marker for the development of coronary events.

###### 

Carbohydrate and lipid metabolism markers

                                          Risperidone-treated patients                            Olanzapine-treated patients
  --------------------------------------- ------------------------------------------------------- --------------------------------------------------------
                                          n = 9                                                   n = 9
  Glucose (mg/dL)-- fasting               88.1 ± 8.1                                              92.6 ± 10.5
   • after glucose tolerance cookie       99.6 ± 9.7                                              109.0 ± 15.0[\*](#tfn2-ndt-3-177){ref-type="table-fn"}
  Insulin (μU/L)--fasting                 5.4 ± 2.6                                               5.5 ± 3.3
   • after glucose tolerance cookie       7.8 ± 1.8[\*\*](#tfn3-ndt-3-177){ref-type="table-fn"}   9.1± 2.3[\*](#tfn2-ndt-3-177){ref-type="table-fn"}
  Triglycerides (mg/dL)--fasting          120.9 ± 27.4                                            130.4 ± 33.6
   • after glucose tolerance cookie       132.6 ± 24.2                                            171.2 ± 41.7[\*](#tfn2-ndt-3-177){ref-type="table-fn"}
  Total cholesterol (mg/dL)--fasting      165.2 ± 42.4                                            171.2 ± 34.5
  HDL cholesterol (mg/dL)--fasting        48.8 ±12.7                                              48.2 ±13.1
  RLP-cholesterol (mg/dL)                 4.3 ± 1.6                                               7.5 ± 1.0 [†](#tfn4-ndt-3-177){ref-type="table-fn"}
  Insulin resistance (HOMA-IR)--fasting   1.19 ± 0.6                                              1.23 ± 0.7

All values are mean ± SD.

p \< 0.05

p \< 0.01 compared with fasting values.

p \< 0.05 compared with risperidone.
